Company intelligence / Profile preview

Eubulus Biotherapeutics

Jiaxing, Zhejiang, Chinapublications.gc.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

Eubulus Biotherapeutics is an early-stage biotech company developing targeted protein degradation therapies using its proprietary TED platform and PROTACs technology. The company has filed several patents related to oncology therapeutics, including a Gpx4 inhibitor in combination with anticancer agents for treating proliferative diseases. It has entered into strategic collaborations and licensing agreements but has not yet reported clinical trial results or commercialized products

Therapeutic areas: Oncology
Modalities: Targeted protein degradation (PROTACs, TED platform)Small molecules (e.g., Gpx4 inhibitor)Enzymatic degradation drugs
Industry: Biotech

Partnerships

Coherent Biopharma (strategic collaboration/licensing agreement for dual-targeted protein degradation molecule from the TED platform)Viva BioInnovator is an investor/incubator partner

Beyond the preview

Go deeper on Eubulus Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eubulus Biotherapeutics.

Explore the full profile